For example, IDH-wt mutations in previously defined WHO grade II gliomas tend to be treated as glioblastomas, although growing evidence suggests that this is an inhomogeneous group, that needs to be further stratified.60,61. This evidence concerns the gene IDH1 and central nervous system cancer.